Bausch Health Companies Inc
BHC
View Detailed Chart
6.730USD
-0.160-2.32%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
2.49BMarket Cap
25.39P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.32%
5 Days
-7.30%
1 Month
-13.61%
6 Months
-3.86%
Year to Date
-16.50%
1 Year
-17.73%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Hold
Current Rating
7.083
Target Price
+2.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.48% year-on-year.
Overvalued
The company’s latest PE is 25.39, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 269.81M shares, decreasing 11.68% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.72.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Ticker SymbolBHC
CompanyBausch Health Companies Inc
CEOMr. Thomas J. Appio
Websitehttps://www.bauschhealth.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
